Lung Cancer

Dr. Vokes provides information about integrating a new chemotherapeutic agent, vinorelbine (Navelbine), into the current treatment regimens for patients with advanced-stage non-small-cell lung cancer. He reviews the phase II activity of

Meta-analyses of randomized clinical studies comparing combination chemotherapy versus "best supportive care" for advanced non-small-cell lung cancer have revealed a small, but statistically significant survival

Researchers at University of Texas Southwestern Medical Center at Dallas reported that alterations in the genes of a section of chromosome 3p may reveal the earliest stages of lung cancer.

Researchers at University of Texas Southwestern Medical Center at Dallas reported that alterations in the genes of a section of chromosome 3p may reveal the earliest stages of lung cancer

PARIS, France--Overexpression of growth factor receptors correlates with a poor prognosis in many malignancies, including breast, bladder, and lung cancer, and new evidence suggests that growth factor receptors may be an important target for anticancer therapy, John Mendelsohn, MD, said at the Fifth International Congress on Anti-Cancer Chemotherapy.

If a woman smoked, contracted breast cancer, and was treated with radiation before 1980, her risk of lung cancer has been dramatically increased. Even if she did not smoke, her chances for lung

COLLEGEVILLE, Penn--A patient with advanced non-small-cell lung cancer has become the first to receive an injection of a p53/retrovirus gene therapy into existing tumor cells, Introgen Therapeutics, Inc. and RPR Gencell, a division of Rhône-Poulenc Rorer, have announced.

This excellent, concise review of the status of lung cancer chemoprevention complements a benchmark review of the whole field of chemoprevention by Drs. Benner, Lippman, Hong and colleagues that appeared recently in the Journal of Clinical Oncology [1] Careful scrutiny of both these articles yields a number of issues for consideration.

Clinical trials have suggested that retinoid chemoprevention prevents the development of second primary tumors following head and neck or non-small-cell lung cancer. The findings of these initial studies are now being

The lack of effective treatments for advanced cancer has been one of the motivating forces in the field of cancer prevention. Nowhere is this approach more justified than in primary pulmonary neoplasms. In this article, Benner and his M.D. Anderson colleagues review trials investigating the prevention of lung cancer utilizing retinoids and carotenoids.

RESEARCH TRIANGLE PARK, NC--Navelbine (vinorelbine tartrate), a semisynthetic vinca alkaloid, has become the first new treatment to receive FDA approval for inoperable advanced non-small-cell lung cancer (NSCLC) in 20 years, Burroughs Wellcome Co., manufacturer of Navelbine, announced at a telephone news conference.

ROCKVILLE, Md--In a surprise move, the FDA Oncologic Drugs Advisory Committee failed to recommend approval of Taxotere (docetaxel, Rhône-Poulenc Rorer) for commercial use.

Survival and local control rates for limited stage small-cell lung cancer patients treated with either once-daily or twice-daily thoracic radiation plus cisplatin (Platinol) and etoposide (VePesid) are substantially better than with previously reported

Preliminary clinical results with gemcitabine, an investigational difluoronucleoside, were presented during scientific sessions organized by the 7th World Conference on Lung Cancer, which was held in Colorado Springs last year. The agent produced

BETHESDA, Md--The FDA has approved Burroughs Wellcome's Navelbine (vinorelbine tartrate) for the first-line treatment of ambulatory patients with unresectable, advanced non-small-cell lung cancer (NSCLC).

ROCKVILLE, Md--To the surprise of many, the FDA Oncology Drugs Advisory Committee recommended that Taxotere (docetaxel, Rhône-Poulenc Rorer) not be approved for marketing at this time. The company was seeking approval of the drug for use in locally advanced or metastatic breast cancer when previous therapy with an anthracycline has failed, and in locally advanced or metastatic non-small-cell lung cancer after failure of platinum-based chemotherapy.